Physostigmine-induced myoclonus in Alzheimer’s disease

Richard Mayeux, Marilyn Albert, Michael Jenike

Research output: Contribution to journalArticle

Abstract

Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

Original languageEnglish (US)
Pages (from-to)345-346
Number of pages2
JournalNeurology
Volume37
Issue number2
StatePublished - 1987
Externally publishedYes

Fingerprint

Physostigmine
Myoclonus
Alzheimer Disease
Muscarinic Receptors
Cholinergic Agents
Neurotransmitter Agents
Clinical Trials
Alzheimer's Disease
Therapeutics

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Mayeux, R., Albert, M., & Jenike, M. (1987). Physostigmine-induced myoclonus in Alzheimer’s disease. Neurology, 37(2), 345-346.

Physostigmine-induced myoclonus in Alzheimer’s disease. / Mayeux, Richard; Albert, Marilyn; Jenike, Michael.

In: Neurology, Vol. 37, No. 2, 1987, p. 345-346.

Research output: Contribution to journalArticle

Mayeux, R, Albert, M & Jenike, M 1987, 'Physostigmine-induced myoclonus in Alzheimer’s disease', Neurology, vol. 37, no. 2, pp. 345-346.
Mayeux, Richard ; Albert, Marilyn ; Jenike, Michael. / Physostigmine-induced myoclonus in Alzheimer’s disease. In: Neurology. 1987 ; Vol. 37, No. 2. pp. 345-346.
@article{8b5596fed1194bf09cd6737b2c296ece,
title = "Physostigmine-induced myoclonus in Alzheimer’s disease",
abstract = "Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.",
author = "Richard Mayeux and Marilyn Albert and Michael Jenike",
year = "1987",
language = "English (US)",
volume = "37",
pages = "345--346",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Physostigmine-induced myoclonus in Alzheimer’s disease

AU - Mayeux, Richard

AU - Albert, Marilyn

AU - Jenike, Michael

PY - 1987

Y1 - 1987

N2 - Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

AB - Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

UR - http://www.scopus.com/inward/record.url?scp=0023113132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023113132&partnerID=8YFLogxK

M3 - Article

C2 - 3808321

AN - SCOPUS:0023113132

VL - 37

SP - 345

EP - 346

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -